NO20072741L - Stabiliserte, individuelt belagte ramiprilpartikler, sammensetninger og fremgangsmater - Google Patents
Stabiliserte, individuelt belagte ramiprilpartikler, sammensetninger og fremgangsmaterInfo
- Publication number
- NO20072741L NO20072741L NO20072741A NO20072741A NO20072741L NO 20072741 L NO20072741 L NO 20072741L NO 20072741 A NO20072741 A NO 20072741A NO 20072741 A NO20072741 A NO 20072741A NO 20072741 L NO20072741 L NO 20072741L
- Authority
- NO
- Norway
- Prior art keywords
- ramipril
- bioavailability
- stabilized
- pharmaceutical
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
Det beskrives nye krystallinske ramiprilpartikler med forbedret stabilitet og biotilgjengelighet.Det gjelder mer spesielt individuelt belagte, krystallinske ramipril enkeltpartikler for farmasøytiske og biofarmasøytiske anvendelser i oral terapi som er stabilisert mot dekomponering til nedbrytningsproduktene, nemlig ramipril-DKP og ramipril-disyre, under formulerings- og lagringsbetingelser.Det beskrives videre farmasøytiske, stabiliserte ramiprilpreparater, nye, vannfrie ramiprilpulvere av farmasøytisk kvalitet, metoder for å forbedre biotilgjengeligheten til rarnipril samt metoder for fremstilling og stabilisering av ramiprilformuleringer.De nye, vannfrie ramiprilpulvere av farmasøytisk kvalitet og ramiprilpreparater og doseringsformer som oppnås ved dette, er nyttige ved behandling av kardiovaskulære forstyrrelser og har fordelen av at de gir større stabilitet mot dekomponering til ramiprilDKP'er og ramipril-disyrer under formulerings- og lagringsbetingelser.I tillegg beholder de konsistent angitt ramiprilpotens over utstrakt lagringstid og gir redusert. in vivo-variasjon i biotilgjengeligheten for ramipril hos individer ved oral administrering.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62527004P | 2004-11-05 | 2004-11-05 | |
PCT/US2005/040429 WO2006050533A2 (en) | 2004-11-05 | 2005-11-07 | Stabilized individually coated ramipril particles, compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072741L true NO20072741L (no) | 2007-08-03 |
Family
ID=36319833
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072739A NO20072739L (no) | 2004-11-05 | 2007-05-30 | Stabiliserte ramiprilsammensetninger og fremgangsmater for fremstilling |
NO20072741A NO20072741L (no) | 2004-11-05 | 2007-05-30 | Stabiliserte, individuelt belagte ramiprilpartikler, sammensetninger og fremgangsmater |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072739A NO20072739L (no) | 2004-11-05 | 2007-05-30 | Stabiliserte ramiprilsammensetninger og fremgangsmater for fremstilling |
Country Status (14)
Country | Link |
---|---|
US (2) | US20060134213A1 (no) |
EP (2) | EP1824451A2 (no) |
JP (2) | JP2008519063A (no) |
KR (2) | KR20070085759A (no) |
CN (2) | CN101098681A (no) |
AU (2) | AU2005304664A1 (no) |
BR (2) | BRPI0517662A (no) |
CA (2) | CA2586760A1 (no) |
IL (2) | IL183017A0 (no) |
MX (2) | MX2007005377A (no) |
NO (2) | NO20072739L (no) |
RU (2) | RU2007120817A (no) |
WO (2) | WO2006052968A2 (no) |
ZA (2) | ZA200704768B (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004019777D1 (de) * | 2003-06-26 | 2009-04-16 | Teva Pharma | STABILE PHARMAZEUTISCHE ZUBEREITUNGEN MIT 2-AZA-BICYCLOi3.3.0 -OCTAN-3-CARBOXYLSÄURE-DERIVATEN |
US6869963B2 (en) * | 2003-07-11 | 2005-03-22 | Sandoz Ag | Stable pharmaceutical compositions containing an ACE inhibitor |
US20080234353A1 (en) * | 2004-03-24 | 2008-09-25 | Reynir Eyjolfsson | Formulations of Ramipril |
EP1824451A2 (en) * | 2004-11-05 | 2007-08-29 | King Pharmaceuticals Research and Development Inc. | Stabilized ramipril compositions and methods of making |
GB0518129D0 (en) * | 2005-09-06 | 2005-10-12 | Arrow Int Ltd | Ramipril formulation |
US20070098782A1 (en) * | 2005-10-28 | 2007-05-03 | Selamine Limited | Ramipril Formulation |
GB2431579A (en) * | 2005-10-28 | 2007-05-02 | Arrow Int Ltd | Ramipril formulations |
EP1948136A1 (en) * | 2005-11-07 | 2008-07-30 | King Pharmaceuticals Research and Development, Inc. | Compositions of stabilized ramipril in combination with another active agent |
JP2009533461A (ja) * | 2006-04-19 | 2009-09-17 | テバ ファーマシューティカル インダストリーズ リミティド | 2−アザ−ビシクロ[3.3.0]−オクタン−3−カルボン酸誘導体の安定な医薬組成物 |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
WO2008134047A1 (en) * | 2007-04-27 | 2008-11-06 | King Pharmaceuticals Research And Development, Inc. | Methods of treating hypertension |
WO2008132756A1 (en) * | 2007-05-01 | 2008-11-06 | Lupin Limited | Stable pharmaceutical compositions of ramipril |
ITMI20072427A1 (it) * | 2007-12-24 | 2009-06-25 | I P S Internat Products & Ser | Matrce polimerica polivalente a immediata disgregazione per prodotti solidi per uso orale a rilascio modificato e metodo per la sua preparazione |
WO2010030735A2 (en) * | 2008-09-11 | 2010-03-18 | Aethos Pharmaceuticals, Inc. | Stabilized coating for pharmaceutical formulations |
TR200906322A2 (tr) | 2009-08-17 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Çözünürlük ve stabilite özellikleri geliştirilmiş granüller. |
ES2364011B1 (es) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
EP2538924B1 (en) * | 2010-02-24 | 2014-05-21 | Sanofi-Aventis Deutschland GmbH | Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation |
RU2479310C2 (ru) * | 2011-02-09 | 2013-04-20 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция для лечения артериальной гипертензии и застойной сердечной недостаточности и способ ее получения |
CN102139109A (zh) * | 2011-03-30 | 2011-08-03 | 上海蓝药实业有限公司 | 一种质量稳定的血管紧张素转化酶抑制剂的制剂组合物 |
WO2013032002A1 (ja) * | 2011-08-31 | 2013-03-07 | 株式会社 奈良機械製作所 | 固体粒子の表面改質装置および固体粒子の表面改質方法 |
BR112014020184B1 (pt) * | 2012-02-17 | 2021-11-30 | Egis Gyógyszergyár Zrt | Preparação farmacêutica que contém anlodipina e ra-mipril |
WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
HUP1300496A2 (hu) | 2013-08-16 | 2015-03-02 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Stabil kombinációs gyógyszerkészítmény |
JP6323846B2 (ja) * | 2016-04-07 | 2018-05-16 | 塩野義製薬株式会社 | オピオイドを含有する乱用防止製剤 |
AU2018258170B2 (en) * | 2017-04-25 | 2023-06-29 | Otsuka Pharmaceutical Co., Ltd. | Lisinopril compositions with an ingestible event marker |
WO2021160700A1 (en) * | 2020-02-10 | 2021-08-19 | Adamed Pharma S.A. | Composition comprising ramipril and indapamide |
KR20240046661A (ko) | 2022-10-01 | 2024-04-09 | 김성현 | 높이 조절 노트북 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3174844D1 (en) * | 1980-10-23 | 1986-07-24 | Schering Corp | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
DE3226768A1 (de) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
DE3300316A1 (de) * | 1983-01-07 | 1984-07-12 | Hoechst Ag, 6230 Frankfurt | Disubstituierte prolinderivate, verfahren zu ihrer herstellung und ihre verwendung |
DE3303112A1 (de) * | 1983-01-31 | 1984-08-09 | Hoechst Ag, 6230 Frankfurt | Verfahren zur racemattrennung optisch aktiver bicyclischer imino-(alpha)-carbonsaeuren |
DE3315464A1 (de) * | 1983-04-28 | 1984-10-31 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern |
DE3333454A1 (de) * | 1983-09-16 | 1985-04-11 | Hoechst Ag, 6230 Frankfurt | Verfahren zur herstellung von n-alkylierten dipeptiden und deren estern |
DE3413710A1 (de) * | 1984-04-12 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur behandlung der herzinsuffizienz |
DE3431541A1 (de) * | 1984-08-28 | 1986-03-06 | Hoechst Ag, 6230 Frankfurt | Cis,endo-2-azabicycloalkan-3-carbonsaeure-derivate, verfahren zu deren herstellung, deren verwendung sowie zwischenprodukte bei deren herstellung |
US5256687A (en) * | 1985-09-09 | 1993-10-26 | Hoechst Aktiengesellschaft | Pharmaceutical composition for the treatment of high blood pressure |
US5231080A (en) * | 1985-10-15 | 1993-07-27 | Hoechst Aktiengesellschaft | Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease |
US5231084A (en) * | 1986-03-27 | 1993-07-27 | Hoechst Aktiengesellschaft | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons |
DE3633496A1 (de) * | 1986-10-02 | 1988-04-14 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln |
DE3639879A1 (de) * | 1986-11-21 | 1988-06-01 | Hoechst Ag | Verfahren zur herstellung von mono-, bi- und tricyclischen aminosaeuren, zwischenprodukte dieses verfahrens sowie ein verfahren zu deren herstellung |
DE3722007A1 (de) * | 1987-07-03 | 1989-01-12 | Hoechst Ag | Verfahren zur herstellung bicyclischer aminocarbonsaeuren, zwischenprodukte dieses verfahrens und deren verwendung |
DE3739690A1 (de) * | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
DE3818245A1 (de) * | 1988-05-28 | 1989-12-07 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln |
DE3926606A1 (de) * | 1989-08-11 | 1991-02-14 | Hoechst Ag | Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie |
TW197945B (no) * | 1990-11-27 | 1993-01-11 | Hoechst Ag | |
US5562921A (en) * | 1994-07-15 | 1996-10-08 | Sherman; Bernard C. | Stable solid pharmaceutical compositions containing enalapril maleate |
TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
US6096339A (en) * | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
DE19737224A1 (de) * | 1997-08-27 | 1999-03-18 | Hoechst Marion Roussel De Gmbh | Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen |
NZ514890A (en) * | 1999-03-31 | 2003-05-30 | Janssen Pharmaceutica Nv | Pregelatinized starch in a controlled release formulation |
SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
HUP0203326A3 (en) * | 1999-08-30 | 2003-04-28 | Sanofi Aventis Deutschland | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
FR2824477B1 (fr) * | 2001-05-09 | 2005-09-09 | Ethypharm Lab Prod Ethiques | Granules enrobes a base d'inhibiteur de l'enzyme de conversion de l'anfiotensine, leur procede de preparation et comprimes orodispersibles contenant les granules enrobes |
ES2333645T3 (es) * | 2001-06-22 | 2010-02-25 | Bend Research, Inc. | Composiciones farmaceuticas de dispersiones de medicamentos y polimeros neutros. |
BR0210520A (pt) * | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros |
JP2004534811A (ja) * | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | ポリマーと薬剤の集合体を含む医薬組成物 |
WO2003013609A1 (en) * | 2001-08-03 | 2003-02-20 | Takeda Chemical Industries, Ltd. | Sustained-release medicines |
EP1428022A1 (en) * | 2001-09-12 | 2004-06-16 | National Research Council of Canada | A method for the simultaneous and direct determination of serum cholesterol in high-and low-density lipoproteins using infrared spectroscopy |
US20050065203A1 (en) * | 2001-10-17 | 2005-03-24 | Salim Yusuf | Method of reducing type 2 diabetes in high risk patients |
US20030138486A1 (en) * | 2001-10-29 | 2003-07-24 | King Pharmaceuticals Research | Methods and dosage forms for improving the bioavailability of therapeutic agents |
EP1653929A1 (en) * | 2003-01-22 | 2006-05-10 | Sandoz AG | Solid pharmaceutical composition comprising ramipril |
DE602004019777D1 (de) * | 2003-06-26 | 2009-04-16 | Teva Pharma | STABILE PHARMAZEUTISCHE ZUBEREITUNGEN MIT 2-AZA-BICYCLOi3.3.0 -OCTAN-3-CARBOXYLSÄURE-DERIVATEN |
EP1824451A2 (en) * | 2004-11-05 | 2007-08-29 | King Pharmaceuticals Research and Development Inc. | Stabilized ramipril compositions and methods of making |
GB0518129D0 (en) * | 2005-09-06 | 2005-10-12 | Arrow Int Ltd | Ramipril formulation |
-
2005
- 2005-11-07 EP EP05826288A patent/EP1824451A2/en not_active Withdrawn
- 2005-11-07 RU RU2007120817/15A patent/RU2007120817A/ru not_active Application Discontinuation
- 2005-11-07 KR KR1020077012632A patent/KR20070085759A/ko not_active Application Discontinuation
- 2005-11-07 US US11/269,388 patent/US20060134213A1/en not_active Abandoned
- 2005-11-07 AU AU2005304664A patent/AU2005304664A1/en not_active Abandoned
- 2005-11-07 WO PCT/US2005/040430 patent/WO2006052968A2/en active Application Filing
- 2005-11-07 ZA ZA200704768A patent/ZA200704768B/xx unknown
- 2005-11-07 MX MX2007005377A patent/MX2007005377A/es not_active Application Discontinuation
- 2005-11-07 KR KR1020077012627A patent/KR20070085754A/ko not_active Application Discontinuation
- 2005-11-07 EP EP05851434A patent/EP1817007A2/en not_active Withdrawn
- 2005-11-07 JP JP2007540170A patent/JP2008519063A/ja active Pending
- 2005-11-07 CA CA002586760A patent/CA2586760A1/en not_active Abandoned
- 2005-11-07 US US11/269,387 patent/US20060159742A1/en not_active Abandoned
- 2005-11-07 MX MX2007005373A patent/MX2007005373A/es not_active Application Discontinuation
- 2005-11-07 CA CA002586547A patent/CA2586547A1/en not_active Abandoned
- 2005-11-07 CN CNA2005800460678A patent/CN101098681A/zh active Pending
- 2005-11-07 ZA ZA200704767A patent/ZA200704767B/xx unknown
- 2005-11-07 CN CNA2005800460767A patent/CN101098679A/zh active Pending
- 2005-11-07 AU AU2005301989A patent/AU2005301989A1/en not_active Abandoned
- 2005-11-07 WO PCT/US2005/040429 patent/WO2006050533A2/en active Application Filing
- 2005-11-07 RU RU2007120821/15A patent/RU2007120821A/ru not_active Application Discontinuation
- 2005-11-07 JP JP2007540169A patent/JP2008519062A/ja active Pending
- 2005-11-07 BR BRPI0517662-0A patent/BRPI0517662A/pt not_active Application Discontinuation
- 2005-11-07 BR BRPI0517663-8A patent/BRPI0517663A/pt not_active Application Discontinuation
-
2007
- 2007-05-06 IL IL183017A patent/IL183017A0/en unknown
- 2007-05-06 IL IL183018A patent/IL183018A0/en unknown
- 2007-05-30 NO NO20072739A patent/NO20072739L/no not_active Application Discontinuation
- 2007-05-30 NO NO20072741A patent/NO20072741L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070085754A (ko) | 2007-08-27 |
WO2006050533A3 (en) | 2006-09-14 |
MX2007005377A (es) | 2008-01-11 |
WO2006052968A3 (en) | 2006-10-12 |
EP1824451A2 (en) | 2007-08-29 |
KR20070085759A (ko) | 2007-08-27 |
US20060159742A1 (en) | 2006-07-20 |
CN101098681A (zh) | 2008-01-02 |
AU2005304664A1 (en) | 2006-05-18 |
ZA200704768B (en) | 2008-08-27 |
IL183018A0 (en) | 2007-09-20 |
BRPI0517662A (pt) | 2008-10-14 |
BRPI0517663A (pt) | 2008-10-14 |
JP2008519063A (ja) | 2008-06-05 |
EP1817007A2 (en) | 2007-08-15 |
CA2586547A1 (en) | 2006-05-11 |
RU2007120817A (ru) | 2008-12-10 |
IL183017A0 (en) | 2007-09-20 |
CN101098679A (zh) | 2008-01-02 |
AU2005301989A1 (en) | 2006-05-11 |
ZA200704767B (en) | 2008-08-27 |
CA2586760A1 (en) | 2006-05-18 |
NO20072739L (no) | 2007-07-24 |
US20060134213A1 (en) | 2006-06-22 |
WO2006052968A2 (en) | 2006-05-18 |
RU2007120821A (ru) | 2008-12-10 |
JP2008519062A (ja) | 2008-06-05 |
WO2006050533A2 (en) | 2006-05-11 |
MX2007005373A (es) | 2007-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072741L (no) | Stabiliserte, individuelt belagte ramiprilpartikler, sammensetninger og fremgangsmater | |
WO2006133941A3 (en) | Cannabinoid active pharmaceutical ingredient for improved dosage forms | |
CA3094580A1 (en) | Oral formulations of cytidine analogs and methods of use thereof | |
EP2201947A3 (en) | Use of SAHA for treating mesothelioma | |
WO2002074247A3 (en) | Pharmaceutical formulations for sustained release | |
WO2007022255A3 (en) | Pharmaceutical formulations for sustained release | |
WO2006070325A3 (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
NZ591873A (en) | Co-crystals of tramadol and nsaids | |
NO20100301L (no) | Forbedrete brimonidinsammensetninger for behandling av erytem | |
WO2007014124A3 (en) | High drug load formulations and dosage forms | |
TW200738228A (en) | Neramexane modified release matrix tablet | |
GB0814302D0 (en) | Compounds and methods | |
WO2007021970A3 (en) | Stable pharmaceutical formulations and methods of use thereof | |
WO2009077741A3 (en) | 3-substituted-4-0x0-3, 4-dihydro-imidazo- [5, 1-d] [1,2,3,5] -tetrazine-8-carboxylic acid amides as anticancer agents | |
SG147450A1 (en) | Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof | |
SI1730144T1 (sl) | Substituirane spojine 1,4,8-triazaspiro(4.5)dekan-2-on | |
MX2009010675A (es) | Formulaciones farmaceuticas de moleculas de la hormona liberadora de la hormona delcrecimiento humana. | |
CN110996949A (zh) | 用于治疗行为改变的方法 | |
MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
US20230105108A1 (en) | Compounds for the treatment of bacterial infections and potentiation of antibiotics | |
NO20090067L (no) | Farmasoytiske kombinasjoner for behandling av respiratoriske sykdommer | |
WO2005100384A3 (en) | Ai-2 compounds and analogs based on salmonella typhimurium lsrb structure | |
CA2547866A1 (en) | Farnesyl dibenzodiazepinone formulation | |
WO2004098577A3 (en) | Dosage form containing (s)-pantoprazole as active ingredient | |
WO2007044574A3 (en) | Pharmaceutical compositions, methods of preparation thereof, and methods of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |